Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase 1 Terminated
28 enrolled
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Phase 1 Terminated
28 enrolled 19 charts
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
Phase 1 Terminated
1 enrolled
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Terminated
11 enrolled
DC15-MM-01
Phase 1 Terminated
4 enrolled
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 Terminated
12 enrolled
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Phase 1 Terminated
12 enrolled
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
Phase 1 Terminated
3 enrolled
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
66 enrolled
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
141 enrolled 46 charts
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
A Study to Investigate LYL845 in Adults With Solid Tumors
Phase 1 Terminated
39 enrolled
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
45 enrolled
MK-0482-002
Phase 1 Terminated
13 enrolled 19 charts
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Phase 1 Terminated
62 enrolled
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
183 enrolled
MCLA-117 in Acute Myelogenous Leukemia
Phase 1 Terminated
80 enrolled
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
26 enrolled
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Phase 1 Terminated
45 enrolled
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Phase 1 Terminated
13 enrolled
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Phase 1 Terminated
4 enrolled 6 charts
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Phase 1 Terminated
16 enrolled
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Phase 1 Terminated
64 enrolled
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
60 enrolled
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Terminated
9 enrolled
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
3 enrolled
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase 1 Terminated
139 enrolled
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
19 enrolled 22 charts
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Phase 1 Terminated
11 enrolled
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
47 enrolled
ARMY
Phase 1 Terminated
71 enrolled 26 charts
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Phase 1 Terminated
1 enrolled
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
Phase 1 Terminated
20 enrolled
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
1 enrolled 2 charts
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
5 enrolled
DIPG
Phase 1 Terminated
4 enrolled
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Phase 1 Terminated
4 enrolled
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
Phase 1 Terminated
12 enrolled
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Phase 1 Terminated
6 enrolled 11 charts
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
Phase 1 Terminated
92 enrolled
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
ZUMA-8
Phase 1 Terminated
16 enrolled 17 charts
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1 Terminated
30 enrolled
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Phase 1 Terminated
9 enrolled
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Phase 1 Terminated
5 enrolled
Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT
Phase 1 Terminated
11 enrolled
NK Cell Therapy for AML
Phase 1 Terminated
3 enrolled